Corbus Pharmaceuticals Holdings (CRBP) Gains from Investment Securities (2013 - 2019)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Gains from Investment Securities of -$69821.0 for Q4 2019, down 303.65% year-over-year from $34284.0 in Q4 2018, and down 160.06% quarter-over-quarter from $116245.0 in Q3 2019.
Corbus Pharmaceuticals Holdings (CRBP) Gains from Investment Securities (2013 - 2019) Analysis & Trends
Corbus Pharmaceuticals Holdings' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$69821.0 for Q4 2019.
- In Q4 2019, Gains from Investment Securities fell 303.65% year-over-year to -$69821.0; the TTM figure through Dec 2019 stood at $45833.0 (down 34.94% YoY), while the FY2019 annual figure was $45833.0, down 34.94% from the prior year.
- Gains from Investment Securities for Q4 2019 stood at -$69821.0, down from $116245.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $116245.0 in Q3 2019, with the low at -$69821.0 in Q4 2019.
- The 4-year median for Gains from Investment Securities is $11983.5 (2017), against an average of $9731.4.
- Peak annual rise in Gains from Investment Securities reached 2688.98% in 2019, while the deepest fall reached 303.65% in 2019.
- Corbus Pharmaceuticals Holdings' Gains from Investment Securities stood at $26930.0 in 2015, then tumbled by 278.17% to -$47982.0 in 2017, then surged by 171.45% to $34284.0 in 2018, then sank by 303.65% to -$69821.0 in 2019.
- Business Quant data shows CRBP's Gains from Investment Securities at -$69821.0 in Q4 2019, $116245.0 in Q3 2019, and -$13964.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -69,821.00 |
| Dec 31, 2019 | -69,821.00 |
| Sep 30, 2019 | 116,245.00 |
| Sep 30, 2019 | 116,245.00 |
| Jun 30, 2019 | -13,964.00 |
| Jun 30, 2019 | -13,964.00 |
| Mar 31, 2019 | 13,373.00 |
| Mar 31, 2019 | 13,373.00 |
| Dec 31, 2018 | 34,284.00 |
| Dec 31, 2018 | 34,284.00 |
| Sep 30, 2018 | -4,490.00 |
| Sep 30, 2018 | -4,490.00 |
| Jun 30, 2018 | 31,409.00 |
| Jun 30, 2018 | 31,409.00 |
| Mar 31, 2018 | 9,245.00 |
| Mar 31, 2018 | 9,245.00 |
| Dec 31, 2017 | -47,982.00 |
| Dec 31, 2017 | -47,982.00 |
| Sep 30, 2017 | 14,633.00 |
| Sep 30, 2017 | 14,633.00 |